Drugs of Abuse Pharmacology

Understanding the pharmacology of abused substances is essential for any medical professional. You will encounter patients whose health is compromised by substance use, and knowing the precise mechanisms, toxicities, and treatments allows for accurate diagnosis, effective intervention, and compassionate care. This knowledge bridges basic neurobiology with clinical practice, empowering you to address one of medicine's most complex challenges.

Neurobiological Foundations of Addiction

Addiction is a chronic brain disorder characterized by compulsive drug-seeking despite harmful consequences. Its neurobiology centers on the brain's reward pathway, primarily involving the mesolimbic dopamine system. When a rewarding stimulus, like a drug, is encountered, dopamine is released in the nucleus accumbens, reinforcing the behavior. Drugs of abuse hijack this system by artificially and powerfully increasing synaptic dopamine or other neurotransmitter levels, leading to euphoria and driving repeated use. Over time, chronic exposure induces neuroadaptations, including changes in receptor density and signaling pathways. These alterations underlie tolerance (needing more drug for the same effect) and dependence (the body's adaptation requiring the drug to function normally). The transition from voluntary use to compulsive addiction involves shifts in brain circuitry from reward-based learning to habitual and stress-driven systems, particularly affecting the prefrontal cortex, which governs judgment and impulse control.

Pharmacodynamics of Major Drug Classes

Each class of abused drug produces its characteristic effects by interacting with specific neurotransmitter systems. Recognizing these mechanisms helps you predict clinical presentations and potential toxicities.

Stimulants: Cocaine and Methamphetamine Cocaine produces intense euphoria and alertness by blocking the dopamine transporter (DAT). This dopamine reuptake inhibition causes dopamine to accumulate in the synapse, overstimulating postsynaptic receptors. In contrast, methamphetamine primarily enters presynaptic neurons and forces the release of stored catecholamines (dopamine, norepinephrine) while also blocking their reuptake. This massive surge leads to prolonged stimulation, manifesting as increased energy, decreased appetite, and hyperthermia. Both drugs can cause hypertension, tachycardia, arrhythmias, and in severe cases, stroke or myocardial infarction due to excessive sympathetic nervous system activation.

Entactogens: MDMA 3,4-Methylenedioxymethamphetamine (MDMA), often called ecstasy, has a unique mechanism. It primarily induces the release of serotonin (5-HT) from presynaptic vesicles and inhibits its reuptake. This flood of serotonin is responsible for the drug's empathogenic and prosocial effects. However, it also causes a secondary release of dopamine and norepinephrine. The massive depletion of serotonin after use contributes to the profound dysphoria and cognitive "crash" experienced in the following days. Neurotoxicity, particularly to serotonin neurons, is a major concern with repeated use.

Depressants: Opioids, Cannabis, and Alcohol This diverse group slows central nervous system (CNS) function. Heroin, a prodrug rapidly converted to morphine, exerts its effects by agonizing mu-opioid receptors. This activation inhibits GABAergic interneurons, disinhibiting dopamine release in the reward pathway, causing euphoria and analgesia. It also suppresses brainstem respiratory centers, which is the primary cause of fatal overdose.

Cannabis contains delta-9-tetrahydrocannabinol (THC), which acts as a partial agonist at CB1 receptors. These receptors are densely located in the brain's cerebellum, basal ganglia, and hippocampus. CB1 receptor activation inhibits neurotransmitter release, leading to the drug's characteristic euphoria, altered perception, impaired memory, and motor coordination deficits.

Alcohol has a broad, non-specific mechanism. It positively modulates GABA_A receptors, enhancing the inhibitory effect of GABA, which sedates the CNS. Concurrently, it inhibits NMDA receptors, which are glutamate receptors responsible for excitatory signaling. This dual action—GABA enhancement and NMDA inhibition—explains alcohol's sedative, anxiolytic, and amnesic effects. Chronic use leads to receptor adaptations that precipitate withdrawal when alcohol is absent.

Clinical Manifestations: Intoxication and Withdrawal

Recognizing the syndromes of acute intoxication and withdrawal is a critical diagnostic skill. Consider this vignette: A patient presents with agitation, paranoia, chest pain, and a body temperature of 39.5°C. Their pupils are dilated. This picture is classic for stimulant (e.g., methamphetamine) intoxication, driven by catecholamine excess. Withdrawal syndromes occur when a dependent individual reduces or stops drug use, leading to a rebound hyperactivity of the systems the drug suppressed.

Opioid withdrawal, while not typically life-threatening, is extremely distressing. Symptoms include piloerection ("cold turkey"), lacrimation, rhinorrhea, yawning, diaphoresis, nausea, vomiting, diarrhea, and intense drug craving. It results from noradrenergic hyperactivity in the locus coeruleus, which is no longer inhibited by opioid receptor activation.

Alcohol and benzodiazepine withdrawals are medically dangerous. As the CNS adapts to chronic GABA enhancement by reducing receptor sensitivity, abrupt removal of the drug leaves the brain in a hyperexcitable state. This can progress from anxiety and tremor to seizures and delirium tremens (DTs), characterized by autonomic instability, hallucinations, and confusion. DTs have a significant mortality rate if untreated.

Cannabis withdrawal is often underrecognized but includes irritability, sleep disturbance, decreased appetite, and restlessness. MDMA and cocaine withdrawal are marked primarily by dysphoria, anhedonia, fatigue, and increased sleep.

Overdose Management and Treatment Strategies

Effective management of acute overdose is a lifesaving intervention. For opioid overdose, the cornerstone is the rapid administration of naloxone, a competitive mu-opioid receptor antagonist. It reverses respiratory depression within minutes. However, its duration of action is shorter than that of many opioids, so patients must be monitored for renarcotization. Stimulant overdose management is supportive: controlling agitation with benzodiazepines, treating hyperthermia with active cooling, and managing hypertension and arrhythmias as needed.

Long-term treatment for substance use disorders often involves medication-assisted treatment (MAT). For opioid use disorder, methadone and buprenorphine are first-line. Methadone is a full mu-opioid agonist that prevents withdrawal and craving without producing significant euphoria when taken orally at stable doses. Buprenorphine is a partial agonist; it has a high affinity for the mu-opioid receptor but a ceiling effect on respiratory depression, making it safer in overdose. Both medications reduce illicit opioid use, mortality, and transmission of infectious diseases by stabilizing neurochemistry. For alcohol use disorder, medications like naltrexone (an opioid antagonist), acamprosate (modulates glutamate), and disulfiram (causes an aversive reaction to alcohol) can be used as part of a comprehensive treatment plan.

Common Pitfalls

1. Misattributing Psychiatric Symptoms: Anxiety, paranoia, or depression in a patient may be solely attributed to a primary mental health disorder without considering substance-induced effects. Correction: Always take a thorough substance use history and consider a period of monitored abstinence to clarify the diagnosis. For example, stimulant-induced psychosis can resemble schizophrenia but typically resolves after the drug is cleared.
2. Inadequate Withdrawal Management: Under-dosing or prematurely discontinuing benzodiazepines in alcohol withdrawal can lead to seizures and DTs. Correction: Use a standardized protocol like the CIWA-Ar scale to objectively assess symptoms and titrate benzodiazepine doses accordingly, ensuring a gradual, controlled taper.
3. Overlooking Polysubstance Use: Patients often use more than one drug, which can mask or alter typical presentations. A patient using both opioids and benzodiazepines has a dramatically higher risk of fatal respiratory depression. Correction: Use comprehensive urine toxicology screens and ask specifically about combinations. Management must address all substances involved.
4. Stigmatizing Medication-Assisted Treatment: Viewing methadone or buprenorphine as merely "substituting one drug for another" is a harmful misconception that denies patients effective care. Correction: Frame MAT correctly: it is a evidence-based medical treatment that normalizes brain function, reduces harm, and allows patients to engage in recovery. It is analogous to using insulin for diabetes.

Summary

• Drugs of abuse produce their effects by directly manipulating key neurotransmitter systems: cocaine inhibits dopamine reuptake, methamphetamine releases catecholamines, MDMA releases serotonin, heroin activates mu-opioid receptors, cannabis agonizes CB1 receptors, and alcohol enhances GABA while inhibiting NMDA receptors.
• Addiction involves long-term neuroadaptations in the brain's reward, stress, and executive control circuits, leading to compulsive use.
• Withdrawal syndromes are predictable rebound phenomena; opioid withdrawal is distressing, while alcohol and benzodiazepine withdrawal can be life-threatening.
• Acute overdose management requires specific antagonists (e.g., naloxone for opioids) and supportive care (e.g., benzodiazepines and cooling for stimulants).
• Medication-assisted treatment with methadone or buprenorphine is a foundational, life-saving strategy for opioid use disorder, stabilizing brain chemistry and improving long-term outcomes.